LOTEMAX (loteprednol etabonate) by Bausch + Lomb is clinical pharmacology corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
LOTEMAX (loteprednol etabonate) is a corticosteroid ophthalmic suspension administered as eye drops that reduces inflammation by inhibiting phospholipase A2 and suppressing prostaglandin and leukotriene production. It is indicated for seasonal allergic conjunctivitis and post-operative inflammation, with rapid onset of symptom relief within 2 hours. The drug is structurally modified to undergo predictable metabolism to inactive carboxylic acid metabolites, minimizing systemic absorption.
Product is approaching loss of exclusivity with modest Part D spending ($11M) and limited claims volume, suggesting mature market positioning with declining team investment potential.
CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen,…
Worked on LOTEMAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on LOTEMAX offers stable but declining career trajectory typical of mature ophthalmic franchises; roles focus on defensive market share protection and managed care negotiations rather than innovation or growth. Long-term career development may require lateral moves as the product approaches generics and team investment declines.